Toxin Or Toxoid, Except Endotoxin (e.g., Exotoxin, Enterotoxin, Etc.) Patents (Class 424/236.1)
-
Patent number: 11865135Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to ?-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more ?-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such ?-1,6-glucan conjugates. In certain embodiments, a ?-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.Type: GrantFiled: December 5, 2017Date of Patent: January 9, 2024Assignee: Innate Biotherapeutics, LLCInventors: Gabriel Oscar Reznik, John James Kane, James Michael Siedlecki, Zuzana Dostalova, Isabelle Sansal-Castellano, Ifat Rubin-Bejerano, Hua Miao, Eric Steven Furfine
-
Patent number: 11826399Abstract: The present invention provides, among other things, compositions and methods relating to detection and/or treatment cancer (e.g., one or more tumors) that expresses Neuropilin 1 (NRP1). The present invention provides methods of treating cancer that include administering a chlorotoxin agent to a subject (e.g., to a subject suffering from or susceptible to the cancer which may, in some embodiments, be a cancer that expresses NRP1). In some embodiments, a chlorotoxin agent for use in accordance with the present invention can be or comprise a chlorotoxin polypeptide and a payload moiety (e.g., as a covalent conjugate).Type: GrantFiled: September 14, 2018Date of Patent: November 28, 2023Assignee: Eisai Inc.Inventors: Sharon McGonigle, Utpal Majumder, Maarten H. D. Postema
-
Patent number: 11446382Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.Type: GrantFiled: January 7, 2021Date of Patent: September 20, 2022Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 11419924Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier formulated in a water-in-oil Th2-biased adjuvant/delivery system.Type: GrantFiled: September 6, 2021Date of Patent: August 23, 2022Assignee: MERCIA PHARMA, INC.Inventors: Peter Blackburn, Stephen Grimes
-
Patent number: 11351232Abstract: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.Type: GrantFiled: October 30, 2018Date of Patent: June 7, 2022Assignee: REVANCE THERAPEUTICS, INC.Inventors: Stewart A. Thompson, Curtis L. Ruegg, Jacob M. Waugh
-
Patent number: 11304973Abstract: Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments.Type: GrantFiled: January 25, 2017Date of Patent: April 19, 2022Assignees: American Silver, LLC, Dr. Andrew Willoughby Inc.Inventors: Keith William Moeller, Andrew J. M. Willoughby
-
Patent number: 11149246Abstract: Disclosed are methods for lysis of cells that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allow for simplified removal of detergent after lysis, and importantly, limits damage to DNA, such as shearing, that typically results from separate application of conventional lysis methods, yielding improved quality and quantities of genomic DNA (gDNA).Type: GrantFiled: March 7, 2019Date of Patent: October 19, 2021Assignee: Shoreline Biome, LLCInventors: Mark Driscoll, Thomas Jarvie
-
Patent number: 10864231Abstract: Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments.Type: GrantFiled: August 28, 2015Date of Patent: December 15, 2020Assignees: American Silver, LLC, Dr. Andrew Willoughby Inc.Inventors: Andrew J. M. Willoughby, Keith William Moeller
-
Patent number: 10780149Abstract: A new therapeutic use of botulinum neurotoxin serotype A (Bont/A) is described, in the therapeutic treatment of paralysis caused by spinal cord injury.Type: GrantFiled: January 21, 2019Date of Patent: September 22, 2020Assignee: CONSIGLIO NAZIONALE DELLE RICERCHEInventors: Sara Marinelli, Flaminia Pavone, Siro Luvisetto, Valentina Vacca
-
Patent number: 10744098Abstract: Embodiments of the invention relate to particulate agents and compositions comprising particulate agents for inhalation, and methods for preparing such particulate agents and compositions for inhalation, as well as therapeutic methods. Embodiments of the method comprise preparing an emulsion by combining an oil phase dispersion of hydrophobic seed particles and an aqueous dispersion comprising an emulsifier and an emulsion stabilizer and preparing a feedstock comprising encapsulated particles by homogenizing the emulsion, and forming a plurality of coated particles by spray drying the feedstock, wherein resulting particles comprises a porous shell disposed on or over a core and the core comprises at least one hydrophobic seed particle.Type: GrantFiled: March 24, 2015Date of Patent: August 18, 2020Assignee: Novartis AGInventors: Daniel Huang, Nagaraja Rao, Trixie Tan, Danforth Miller, Jeffry Weers
-
Patent number: 10597632Abstract: The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.Type: GrantFiled: July 14, 2017Date of Patent: March 24, 2020Assignee: CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA.Inventors: Marcos Castanheira Alegria, Lucidio Cristovao Fardelone, Marina Baiochi Riboldi Delalana, Josef Ernst Thiemann, Spartaco Astolfi Filho, Roberto Carlos Debom Moreira, Ogari de Castro Pacheco
-
Patent number: 10549042Abstract: The present invention relates to a prefilled glass container, such as a prefilled glass syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled container is stable at low to ambient temperature for a prolonged time period. Furthermore, the present invention relates to a kit comprising the botulinum toxin prefilled container, and to the use of the botulinum toxin prefilled container in therapeutic and cosmetic applications.Type: GrantFiled: December 22, 2015Date of Patent: February 4, 2020Assignee: Merz Pharma GmbH & Co. KGaAInventor: Markus Vogt
-
Patent number: 10537619Abstract: Methods for alleviating osteoarthritis-associated symptoms by selecting a treatment-eligible patient and local administration of a clostridial derivative, such as a botulinum toxin, to an osteoarthritis-affected site are disclosed herein.Type: GrantFiled: August 31, 2015Date of Patent: January 21, 2020Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Guang-Liang Jiang, Ronald E. DeGryse
-
Patent number: 10485603Abstract: Methods and devices for treating nasal airways are provided. Such devices and methods may improve airflow through an internal and/or external nasal valve, and comprise the use of mechanical re-shaping, energy application and other treatments to modify the shape, structure, and/or air flow characteristics of an internal nasal valve, an external nasal valve or other nasal airways.Type: GrantFiled: February 12, 2019Date of Patent: November 26, 2019Assignee: AERIN MEDICAL, INC.Inventors: Scott J. Wolf, Andrew Frazier
-
Patent number: 10406290Abstract: The present invention relates to a prefilled plastic container, such as a plastic syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled plastic container is stable for a prolonged time period. Furthermore, the present invention relates to a kit comprising the prefilled plastic container, and to the use of the prefilled plastic container for therapeutic and cosmetic purposes.Type: GrantFiled: December 22, 2015Date of Patent: September 10, 2019Assignee: Merz Pharma GmbH & Co. KGaAInventor: Markus Vogt
-
Patent number: 10335221Abstract: Methods and devices for treating nasal airways are provided. Such devices and methods may improve airflow through an internal and/or external nasal valve, and comprise the use of mechanical re-shaping, energy application and other treatments to modify the shape, structure, and/or air flow characteristics of an internal nasal valve, an external nasal valve or other nasal airways.Type: GrantFiled: August 25, 2017Date of Patent: July 2, 2019Assignee: AERIN MEDICAL, INC.Inventors: Scott J. Wolf, Andrew Frazier
-
Patent number: 10258673Abstract: The invention relates a pharmaceutical composition containing botulinum toxin and a mucopolysaccharide uses thereof with increased pharmacological activity and long lasting botulinum toxin effect.Type: GrantFiled: May 14, 2014Date of Patent: April 16, 2019Assignee: Bosti Trading Ltd.Inventors: Evgeny Pokushalov, Vladislav Fomenko, Nariman Salakhudinov
-
Patent number: 10240138Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalized and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.Type: GrantFiled: June 11, 2009Date of Patent: March 26, 2019Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Frederic Madec, Phil Lecane, Philip Marks, Keith Foster
-
Patent number: 10201594Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.Type: GrantFiled: May 16, 2016Date of Patent: February 12, 2019Assignee: Revance Therapeutics, Inc.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Patent number: 10076558Abstract: The present invention relates to methods of inhibiting scar formation in a skin wound as well as methods of promoting tissue regeneration in a skin wound in a subject in need thereof comprising administering in or near said wound an effective amount of one or more neurotoxins.Type: GrantFiled: February 18, 2015Date of Patent: September 18, 2018Assignee: RNW SKN, LLCInventors: Joely Kaufman-Janette, Alejandro Cazzaniga
-
Patent number: 10030238Abstract: The invention provides a nucleic acid sequence comprising a sequence of contiguous nucleotides, wherein said sequence of contiguous nucleotides has at least 90% sequence identity to the nucleic acid sequence of SEQ ID NO: 1, and wherein said sequence of contiguous nucleotides encodes a single-chain BoNT/E1 protein. The present invention also provides methods for producing soluble single-chain BoNT/E1 protein in an E. coli host cell, together with methods for producing soluble di-chain BoNT/E1 protein.Type: GrantFiled: October 31, 2013Date of Patent: July 24, 2018Assignees: IPSEN BIOINNOVATION LIMITED, IPSEN BIOPHARM LIMITEDInventors: Aimee Cossins, Matthew Beard, Philip Marks
-
Patent number: 10004789Abstract: A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming a foam. The therapeutic agent is dispersed in the foam which has an expanded configuration adapted to fill a nasopharyngeal space and deliver the therapeutic agent to the mucosa targets. The delivery device is for delivering the foam to the nasopharyngeal space. The foam may also have a collapsed configuration for removal from the nasopharyngeal space or for concentration of the therapeutic agent onto the mucosa.Type: GrantFiled: April 1, 2016Date of Patent: June 26, 2018Assignee: The Foundry LLCInventors: John Morriss, Cary Reich, Hanson Gifford
-
Patent number: 9950045Abstract: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.Type: GrantFiled: December 22, 2016Date of Patent: April 24, 2018Inventor: Eric Finzi
-
Patent number: 9801931Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: GrantFiled: February 23, 2015Date of Patent: October 31, 2017Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Alison D. O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
-
Patent number: 9789176Abstract: This disclosure features compositions that include two or more staphylococcal toxoids and are useful for inducing protective immune responses against staphylococcal diseases.Type: GrantFiled: March 16, 2012Date of Patent: October 17, 2017Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Marnie L. Peterson
-
Patent number: 9764011Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: GrantFiled: March 1, 2016Date of Patent: September 19, 2017Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
-
Patent number: 9725692Abstract: The present invention refers to a culture medium and a process for producing Clostridium collagenolytic and gelatinolytic proteases. The present invention includes an animal product-free culture medium for C. histolyticum comprising non-animal derived peptones, preferably vegetable derived peptones, yeast extract and the amino acids cysteine and arginine. The present invention also includes a process for producing a supernatant of Clostridium histolyticum liquid culture comprising one or more collagenolytic and gelatinolytic proteases, and pharmaceutical composition comprising as active ingredient a supernatant of the Clostridium cultures described herein.Type: GrantFiled: May 29, 2013Date of Patent: August 8, 2017Assignee: CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA.Inventors: Marcos Castanheira Alegria, Lucidio Cristovao Fardelone, Marina Baiochi Riboldi Delalana, Josef Ernst Thiemann, Spartaco Astolfi Filho, Roberto Carlos Debom Moreira, Ogari de Castro Pacheco
-
Patent number: 9598683Abstract: A method for purifying a non-spreading botulinum toxin that causes local muscle paralysis and a non-spreading botulinum toxin obtained thereby includes the steps of: subjecting a purified botulinum toxin type A product to ion-exchange chromatography using a controlled pH of buffer, concentration of sodium chloride (NaCl), thereby separating the botulinum toxin type A product into subfractions; and collecting a subfraction having an A260/A280 value in a specific range from the separated subfractions.Type: GrantFiled: May 13, 2011Date of Patent: March 21, 2017Assignee: MEDEXGEN INCORPORATEDInventors: Yong Hoon Chung, Hyun Sub Lee
-
Patent number: 9579368Abstract: A neuroinhibitory substance for use in a method for treating or preventing headache comprising injecting a neuroinhibitory substance such as botulinium toxin in close proximity to the sphenopalatine ganglion or otic ganglion wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically and the neuroinhibitory substance injected in close proximity to the SPG or OG.Type: GrantFiled: September 6, 2013Date of Patent: February 28, 2017Assignee: Norwegian University of Science and Technology (NTNU)Inventors: Daniel Fossum Bratbak, Ståle Nordgård
-
Patent number: 9533029Abstract: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.Type: GrantFiled: June 22, 2015Date of Patent: January 3, 2017Inventor: Eric Finzi
-
Patent number: 9492558Abstract: Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimizes the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunizing a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 ?g/ml.Type: GrantFiled: April 29, 2005Date of Patent: November 15, 2016Assignee: GlaxoSmithKline Biologicals SAInventor: Paolo Costantino
-
Patent number: 9480732Abstract: The invention provides compositions and methods for treating incontinence associated with sexual activity.Type: GrantFiled: September 25, 2015Date of Patent: November 1, 2016Assignee: Allergan, Inc.Inventor: Mitchell F. Brin
-
Patent number: 9458204Abstract: The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: GrantFiled: August 25, 2005Date of Patent: October 4, 2016Assignee: EPITOPIX LLCInventors: Darren E. Straub, Daryll A. Emery
-
Patent number: 9310368Abstract: High affinity monoclonal antibodies against Stx2 and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting Stx2 and variants thereof in a sample as well as neutralization of Shiga toxin in vivo.Type: GrantFiled: September 27, 2013Date of Patent: April 12, 2016Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Xiaohua He, Larry H. Stanker, Luisa W. Cheng
-
Patent number: 9279001Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: GrantFiled: April 16, 2013Date of Patent: March 8, 2016Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
-
Patent number: 9144600Abstract: The invention provides compositions and methods for treating incontinence associated with sexual activity.Type: GrantFiled: July 13, 2012Date of Patent: September 29, 2015Assignee: Allergan, Inc.Inventor: Mitchell F. Brin
-
Patent number: 9078851Abstract: The present invention relates to a novel use of substance P. The substance P of the present invention exhibits effects of decreasing microglia activity, decreasing proinflammatory cytokines, inhibiting apoptosis, etc. The substance P of the present invention effectively treats degenerative central nervous system diseases or disorders such as a spinal cord injury caused by a traumatic injury (flexion injury, vertical compression injury, hyperextension injury, flexion-rotation injury) and by a non-traumatic injury (vascular dysfunction, arthritis, or degenerative arthritis), Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, depressive disorder, epilepsy, etc.Type: GrantFiled: August 17, 2010Date of Patent: July 14, 2015Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEEInventors: Young Sook Son, Mei Hua Jiang
-
Patent number: 9034337Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: February 23, 2007Date of Patent: May 19, 2015Assignee: Prothena Biosciences LimitedInventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Publication number: 20150110802Abstract: Methods are provided for producing a plurality of antibody species in a single animal, comprising delivering a plurality of antigen species to a single animal, where each antigen species is delivered to the animal at an anatomically distinct location. Also provided are methods for generating an immune response in an animal, where each antigen species is delivered to the animal at an anatomically distinct location, under conditions in which the animal produces a plurality of antibody species, where each antibody species specifically binds to a different antigen species among the plurality of antigen species.Type: ApplicationFiled: February 26, 2013Publication date: April 23, 2015Applicant: Medlmmune, LLCInventors: Partha S. Chowdhury, Chew-Shun Chang
-
Patent number: 8992940Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.Type: GrantFiled: January 18, 2013Date of Patent: March 31, 2015Assignee: Trident Pharmaceuticals, Inc.Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
-
Patent number: 8980283Abstract: The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes methods of making these vaccines.Type: GrantFiled: April 17, 2006Date of Patent: March 17, 2015Assignee: Intervert Inc.Inventors: Huchappa Jayappa, Kevin O'Connell
-
Patent number: 8968747Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: GrantFiled: April 16, 2013Date of Patent: March 3, 2015Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
-
Patent number: 8956812Abstract: A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.Type: GrantFiled: August 23, 2004Date of Patent: February 17, 2015Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Patent number: 8940308Abstract: Disclosed is a method for decreasing depression in a patient by local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles.Type: GrantFiled: February 1, 2013Date of Patent: January 27, 2015Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Mitchell F. Brin
-
Patent number: 8936791Abstract: A method for in vitro diagnosis of Staphylococcus aureus producing Panton-Valentine Leukocidin (PVL), using a biological sample derived from an individual liable to be colonized by or infected with Staphylococcus aureus, wherein the diagnosis is carried out by detection of PVL using a routine immunological test, and the biological sample is pretreated in order to denature the PVL.Type: GrantFiled: October 16, 2007Date of Patent: January 20, 2015Assignees: Biomerieux, Intstitut National de la Sante et de la Recherche Medicale (Inserm), Universite Claude Bernard Lyon 1 (UCBL)Inventors: Cedric Badiou, Jerome Etienne, Gerard Lina, Catherine Ratat
-
Patent number: 8936790Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: GrantFiled: April 16, 2013Date of Patent: January 20, 2015Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
-
Patent number: 8936792Abstract: The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.Type: GrantFiled: September 10, 2010Date of Patent: January 20, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Richard Beers, Masanori Onda
-
Publication number: 20150010579Abstract: The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments of the invention are directed to VLY toxoids and to vaccines that use the new VLY toxoids as immunogens.Type: ApplicationFiled: July 15, 2014Publication date: January 8, 2015Applicant: The Trustees of the University of Columbia in the City of New YorkInventor: Adam J. Ratner
-
Patent number: 8926990Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.Type: GrantFiled: April 13, 2012Date of Patent: January 6, 2015Assignee: Rutgers, The State University of New JerseyInventor: Scott C. Kachlany
-
Patent number: 8920809Abstract: This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject.Type: GrantFiled: August 17, 2010Date of Patent: December 30, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: Joseph M. Dirienzo